AU2002244877B2 - Antitumor compositions containing taxane derivatives - Google Patents

Antitumor compositions containing taxane derivatives Download PDF

Info

Publication number
AU2002244877B2
AU2002244877B2 AU2002244877A AU2002244877A AU2002244877B2 AU 2002244877 B2 AU2002244877 B2 AU 2002244877B2 AU 2002244877 A AU2002244877 A AU 2002244877A AU 2002244877 A AU2002244877 A AU 2002244877A AU 2002244877 B2 AU2002244877 B2 AU 2002244877B2
Authority
AU
Australia
Prior art keywords
combination
compound
treatment
chosen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002244877A
Other languages
English (en)
Other versions
AU2002244877A1 (en
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2002244877A1 publication Critical patent/AU2002244877A1/en
Application granted granted Critical
Publication of AU2002244877B2 publication Critical patent/AU2002244877B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2002244877A 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives Ceased AU2002244877B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
US09/813,018 2001-03-21
PCT/IB2002/000853 WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Publications (2)

Publication Number Publication Date
AU2002244877A1 AU2002244877A1 (en) 2003-03-27
AU2002244877B2 true AU2002244877B2 (en) 2006-07-20

Family

ID=25211230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002244877A Ceased AU2002244877B2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Country Status (19)

Country Link
US (1) US6441026B1 (https=)
EP (1) EP1478355B1 (https=)
JP (1) JP4467885B2 (https=)
CN (2) CN101590057A (https=)
AT (1) ATE355837T1 (https=)
AU (1) AU2002244877B2 (https=)
BR (1) BR0208274A (https=)
CA (1) CA2440160C (https=)
CY (1) CY1106582T1 (https=)
DE (1) DE60218751T2 (https=)
DK (1) DK1478355T3 (https=)
EA (1) EA006878B1 (https=)
ES (1) ES2282400T3 (https=)
HU (1) HUP0500478A2 (https=)
IL (1) IL157992A (https=)
MX (1) MXPA03008539A (https=)
PT (1) PT1478355E (https=)
SI (1) SI1478355T1 (https=)
WO (2) WO2002074232A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
HRPK20041072B3 (hr) * 2002-05-17 2007-07-31 Aventis Pharma S.A. Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
ATE465205T1 (de) * 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
PT2155255E (pt) 2007-05-09 2013-10-15 Nitto Denko Corp Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
KR20130140033A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992019765A1 (en) 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5284865A (en) 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives

Also Published As

Publication number Publication date
ES2282400T3 (es) 2007-10-16
IL157992A (en) 2008-08-07
JP2004536790A (ja) 2004-12-09
CN101590057A (zh) 2009-12-02
EP1478355B1 (en) 2007-03-07
SI1478355T1 (sl) 2007-08-31
US20020031505A1 (en) 2002-03-14
US6441026B1 (en) 2002-08-27
EA200301047A1 (ru) 2004-06-24
CA2440160A1 (en) 2002-09-26
CY1106582T1 (el) 2012-01-25
MXPA03008539A (es) 2004-08-11
DE60218751D1 (de) 2007-04-19
CN1536995A (zh) 2004-10-13
CA2440160C (en) 2011-07-05
DK1478355T3 (da) 2007-07-02
EA006878B1 (ru) 2006-04-28
DE60218751T2 (de) 2007-11-22
HUP0500478A2 (hu) 2005-08-29
WO2002074289A3 (en) 2004-09-02
WO2002074232A2 (en) 2002-09-26
JP4467885B2 (ja) 2010-05-26
ATE355837T1 (de) 2007-03-15
EP1478355A2 (en) 2004-11-24
WO2002074289A2 (en) 2002-09-26
BR0208274A (pt) 2004-07-13
PT1478355E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
AU2002244877B2 (en) Antitumor compositions containing taxane derivatives
US5728687A (en) Antitumour compositions containing taxane derivatives
AU2002244877A1 (en) Antitumor compositions containing taxane derivatives
EP1977753A1 (en) Combined preparation comprising anthracycline derivatives
Saotome et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma
HK1138185A (en) Antitumor compositions containing taxane derivatives
HK1096867A (en) Combined preparations comprising anthracycline derivatives
HK1068786A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired